Clinical Trial: BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
Study Status: Withdrawn
Recruit Status: Unknown status
Study Type: Interventional
Official Title: A Phase II Trial of BIBF1120 in Patients With Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and
Brief Summary: BIBF1120 in patients with advanced FGFR3 mutated, FGFR3 overexpressed, or FGFR3 wild type urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have failed platinum-based chemotherapy.
Detailed Summary:
Sponsor: National Taiwan University Hospital
Current Primary Outcome: Response rate assessed by RECEST version 1.1 [ Time Frame: 2 months ]
Original Primary Outcome: response rate [ Time Frame: 2 months ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: National Taiwan University Hospital
Dates:
Date Received: October 28, 2014
Date Started: October 2014
Date Completion: March 2016
Last Updated: May 10, 2015
Last Verified: May 2015